KR102632060B1 - Composition for preventing alopesia comprising germinated black rice extracts - Google Patents
Composition for preventing alopesia comprising germinated black rice extracts Download PDFInfo
- Publication number
- KR102632060B1 KR102632060B1 KR1020230109336A KR20230109336A KR102632060B1 KR 102632060 B1 KR102632060 B1 KR 102632060B1 KR 1020230109336 A KR1020230109336 A KR 1020230109336A KR 20230109336 A KR20230109336 A KR 20230109336A KR 102632060 B1 KR102632060 B1 KR 102632060B1
- Authority
- KR
- South Korea
- Prior art keywords
- black rice
- fermented
- composition
- fermented pork
- pork potato
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 241000371652 Curvularia clavata Species 0.000 title claims abstract description 47
- 239000000284 extract Substances 0.000 title claims abstract description 46
- 244000061456 Solanum tuberosum Species 0.000 claims abstract description 41
- 235000002595 Solanum tuberosum Nutrition 0.000 claims abstract description 41
- 235000015277 pork Nutrition 0.000 claims abstract description 39
- 230000002500 effect on skin Effects 0.000 claims abstract description 28
- 230000004069 differentiation Effects 0.000 claims abstract description 11
- 230000035755 proliferation Effects 0.000 claims abstract description 11
- 235000012015 potatoes Nutrition 0.000 claims abstract 6
- 238000002360 preparation method Methods 0.000 claims description 40
- 230000036541 health Effects 0.000 claims description 32
- 235000013376 functional food Nutrition 0.000 claims description 26
- 239000002537 cosmetic Substances 0.000 claims description 22
- -1 skin Substances 0.000 claims description 16
- 201000004384 Alopecia Diseases 0.000 claims description 14
- 208000024963 hair loss Diseases 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 12
- 230000003676 hair loss Effects 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 5
- 235000013365 dairy product Nutrition 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 4
- 235000015243 ice cream Nutrition 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 3
- 235000008429 bread Nutrition 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- 235000012149 noodles Nutrition 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000013580 sausages Nutrition 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 235000011888 snacks Nutrition 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 235000014347 soups Nutrition 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 4
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 4
- 230000003752 improving hair Effects 0.000 claims 3
- 230000003779 hair growth Effects 0.000 abstract description 14
- 230000001737 promoting effect Effects 0.000 abstract description 13
- 230000003658 preventing hair loss Effects 0.000 abstract description 12
- 230000003449 preventive effect Effects 0.000 abstract 1
- 239000013543 active substance Substances 0.000 description 38
- 238000004519 manufacturing process Methods 0.000 description 25
- 239000004615 ingredient Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 235000013402 health food Nutrition 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 13
- 229960003632 minoxidil Drugs 0.000 description 13
- 239000008213 purified water Substances 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003778 catagen phase Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003781 hair follicle cycle Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229940117382 propecia Drugs 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000209205 Coix Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241001310492 Pectis angustifolia Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229940070818 glycyrrhizate Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Abstract
본 발명은 발아 흑미 및 발효 돼지감자 복합 추출물을 포함하는 탈모 예방용 조성물에 관한 것으로, 본 발명에 따른 발아 흑미 및 발효 돼지감자 복합 추출물은 모유두 세포의 증식 및 분화를 촉진하는 효능이 우수하므로, 탈모 예방 및 발모 촉진 기능성 조성물로 유용할 수 있다.The present invention relates to a composition for preventing hair loss comprising a complex extract of sprouted black rice and fermented pork potatoes. The complex extract of sprouted black rice and fermented pork potatoes according to the present invention has excellent efficacy in promoting the proliferation and differentiation of dermal papilla cells, thereby preventing hair loss. It can be useful as a preventive and hair growth promoting functional composition.
Description
본 발명은 발아 흑미 및 발효 돼지감자 복합 추출물을 포함하는 탈모 예방용 조성물에 관한 것이다.The present invention relates to a composition for preventing hair loss comprising a complex extract of sprouted black rice and fermented pork potato.
모발은 피부의 부속기관인 모낭이 형성되기 시작하면서 발생되며, 모낭은 포유류의 체표에 존재하는 작은 기관으로 일정한 주기에 따라 변화를 반복한다. 모낭의 주기는 성장기(anagen), 퇴행기(catagen), 휴지기(telogen)로 나뉘는데, 성장기는 모구의 모기질 세포와 멜라닌 형성세포가 증식하면서 모발이 자라게 되고, 퇴행기는 모발의 성장이 종료되고 상피막 수축과 함께 혈액 공급이 중단되고, 휴지기는 모발이 점차 모공 부위까지 밀려 올라가 모발이 탈락하게 된다. Hair is formed when hair follicles, which are appendages to the skin, begin to form. Hair follicles are small organs that exist on the body surface of mammals and repeat changes in a certain cycle. The hair follicle cycle is divided into anagen, catagen, and telogen. In the anagen phase, hair grows as hair matrix cells and melanin-forming cells proliferate, and in the catagen phase, hair growth ends and the epithelial membrane With contraction, blood supply is stopped, and during the resting phase, the hair gradually pushes up to the pore area and the hair falls out.
상술한 모낭의 주기에 따라 모낭주위 면역학적 변화와 호르몬 등의 변화가 동반되는데, 심리적 스트레스, 영양부족, 약물 부작용, 노화 등의 자극 인자에 의해 모낭의 성장기 단축과 퇴행기 조기진행 등이 탈모를 유발할 수 있다.According to the above-mentioned hair follicle cycle, immunological and hormonal changes around the hair follicle are accompanied. Stimulating factors such as psychological stress, lack of nutrition, drug side effects, and aging can cause hair loss by shortening the growth phase of the hair follicle and early progression of the catagen phase. You can.
모발은 외모의 한 부분으로서 대외적인 이미지 개선에 있어 중요한 역할을 하기 때문에, 최근 발모, 양모 및 탈모예방에 대한 연구의 중요성이 높아지고 있는 추세이다. 특히, 생활패턴이 서구화되면서 삶의 질이 개선되고 스트레스가 증가하면서 탈모와 두피질환 등의 고민이 모든 사람의 관심사로 확대되고 있고, 그 원인도 단순한 유전적 요인과 후천적인 요인이 있으며, 이에 대한 중요성과 관심이 점차 커지고 있다. 탈모는 심리적인 위축감 등을 초래하여 대인관계 기피증과 자신감 상실 등으로 이어질 수 있기 때문에 개인의 윤택한 삶 유지에도 많은 영향을 미칠 수 있어 탈모산업 시장은 지속적으로 급성장하고 있는 추세이다.Since hair is a part of one's appearance and plays an important role in improving one's public image, the importance of research on hair growth, hair loss, and hair loss prevention has recently been increasing. In particular, as lifestyle patterns become westernized, quality of life improves, and stress increases, concerns such as hair loss and scalp disease are becoming more of a concern for everyone. The causes are simple genetic factors and acquired factors, and the causes are simple. Importance and interest are gradually growing. Since hair loss can cause psychological withdrawal, which can lead to avoidance of interpersonal relationships and loss of confidence, it can have a significant impact on maintaining an individual's prosperous life, and the hair loss industry market is continuously growing rapidly.
현재 미국 식품 의약품 안전청(FDA)으로부터 승인을 받은 대표적인 탈모치료제로는 합성의약품으로 도포용 미녹시딜과 경구용 프로페시아가 있는데, 이들은 몇 가지 부작용들이 지속적으로 보고되고 있다. 프로페시아는 남성호르몬 (testosterone)에서 탈모의 원인물질인 dihydrotestosterone(DHT)으로 변환되는 과정을 억제하여 효과를 나타내지만 남성의 성욕을 감소시킬 수 있다는 문제가 제기되고 있으며 미녹시딜은 고혈압 치료제로 개발되다가 모낭 활성을 통한 모발 성장 촉진이 보고되면서 양모제로 개발되었지만 다양한 피부질환 등의 부작용이 보고되고 있다.Currently, representative hair loss treatments approved by the U.S. Food and Drug Administration (FDA) include minoxidil for application and Propecia for oral use, which are synthetic drugs, and several side effects are continuously reported. Propecia is effective by inhibiting the process of converting male hormone (testosterone) to dihydrotestosterone (DHT), the causative agent of hair loss, but concerns have been raised that it may reduce men's libido, and minoxidil was developed as a treatment for high blood pressure, but causes hair follicle activation. It was developed as a hair growth agent as it was reported to promote hair growth, but side effects such as various skin diseases have been reported.
다양한 천연물을 이용한 탈모 예방 및 발모 촉진에 관한 연구가 활발하게 이루어지고 있으나, 의약품 대비 낮은 활성으로 인해 발모 촉진제 또는 탈모 억제제의 상용화는 아직 미미한 수준이다.Research on hair loss prevention and hair growth promotion using various natural products is actively being conducted, but commercialization of hair growth promoters or hair loss inhibitors is still minimal due to their lower activity compared to pharmaceuticals.
이에, 본 발명자는 발아 흑미 및 발효 돼지감자 추출물의 혼합물이 모유두 세포의 증식 및 분화를 촉진하는 효능이 우수함을 확인하고 본 발명을 완성하였다.Accordingly, the present inventor confirmed that a mixture of sprouted black rice and fermented pork potato extract was excellent in promoting the proliferation and differentiation of dermal papilla cells and completed the present invention.
본 발명의 목적은 탈모 예방 또는 발모 촉진용 화장료 조성물을 제공하는 것이다.The purpose of the present invention is to provide a cosmetic composition for preventing hair loss or promoting hair growth.
본 발명의 다른 목적은 탈모 예방 또는 발모 촉진용 건강식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health food composition for preventing hair loss or promoting hair growth.
본 발명의 다른 목적은 탈모 예방 또는 발모 촉진용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition for preventing hair loss or promoting hair growth.
본 발명의 다른 목적은 탈모 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating hair loss.
상기 목적을 달성하기 위하여,In order to achieve the above purpose,
본 발명은 발아 흑미 및 발효 돼지감자 복합 추출물을 포함하는 탈모 예방 또는 발모 촉진용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for preventing hair loss or promoting hair growth comprising a complex extract of sprouted black rice and fermented pork potato.
상기 화장료는 화장수, 유액, 크림, 스킨, 로션, 세럼, 에센스, 에멀젼, 파우더, 화장연고, 스프레이, 젤, 팩, 클렌저, 비누, 샴푸, 린스, 입욕제, 세정제 또는 콘실 스틱의 형태일 수 있으나, 이에 제한하지 않는다.The cosmetics may be in the form of lotion, emulsion, cream, skin, lotion, serum, essence, emulsion, powder, cosmetic ointment, spray, gel, pack, cleanser, soap, shampoo, rinse, bath salt, detergent, or concealer stick. It is not limited to this.
또한, 본 발명은 발아 흑미 및 발효 돼지감자 복합 추출물을 포함하는 탈모 예방 또는 발모 촉진용 건강식품 조성물을 제공한다.In addition, the present invention provides a health food composition for preventing hair loss or promoting hair growth comprising a complex extract of sprouted black rice and fermented pork potato.
상기 건강식품은 드링크제, 육류, 소세지, 빵, 캔디류, 스넥류, 면류, 아이스크림, 유제품, 스프, 이온음료, 음료수, 알코올 음료, 껌 또는 차의 형태일 수 있으나, 이에 제한하지 않는다.The health food may be in the form of drinks, meat, sausages, bread, candies, snacks, noodles, ice cream, dairy products, soups, isotonic drinks, beverages, alcoholic beverages, gum or tea, but is not limited thereto.
나아가, 본 발명은 발아 흑미 및 발효 돼지감자 복합 추출물을 포함하는 탈모 예방 또는 발모 촉진용 건강기능식품 조성물을 제공한다.Furthermore, the present invention provides a health functional food composition for preventing hair loss or promoting hair growth comprising a complex extract of sprouted black rice and fermented pork potato.
상기 건강기능식품은 정제, 캡슐제, 환제 또는 액제 형태일 수 있으나, 이에 제한하지 않는다.The health functional food may be in the form of tablets, capsules, pills, or liquid, but is not limited thereto.
또한, 본 발명은 발아 흑미 및 발효 돼지감자 복합 추출물을 포함하는 탈모 예방 또는 치료용 약학적 조성물을 제공한다.Additionally, the present invention provides a pharmaceutical composition for preventing or treating hair loss comprising a complex extract of sprouted black rice and fermented pork potato.
상기 약학적 조성물은 바람직하게는 피부 외용제 형태일 수 있고, 경구투여제로도 응용될 수 있다.The pharmaceutical composition may preferably be in the form of an external application to the skin, and may also be applied as an oral administration agent.
본 발명에 따른 발아 흑미 및 발효 돼지감자 복합 추출물을 모유두 세포의 증식 및 분화를 촉진하는 효능이 우수하므로, 탈모 예방 및 발모 촉진 기능성 조성물로 유용할 수 있다.Since the complex extract of sprouted black rice and fermented pork potato according to the present invention has excellent efficacy in promoting proliferation and differentiation of dermal papilla cells, it can be useful as a functional composition for preventing hair loss and promoting hair growth.
도 1은 실시예 1(발아 흑미 및 발효 돼지감자 복합 추출물) 및 비교예 1(미녹시딜, 'MIX') 처리에 따른 진피 모유두세포에 인위적으로 가한 스크래치 복원 정도를 확인한 이미지이다.
도 2는 실시예 1(발아 흑미 추출물) 및 비교예 1(미녹시딜, 'MIX') 처리에 따른 진피 모유두세포에서 Alkaline Phosphatase 발현량을 확인한 이미지이다.Figure 1 is an image confirming the degree of restoration of scratches artificially applied to dermal dermal papilla cells according to treatment in Example 1 (complex extract of germinated black rice and fermented pork potato) and Comparative Example 1 (minoxidil, 'MIX').
Figure 2 is an image confirming the expression level of Alkaline Phosphatase in dermal dermal papilla cells according to treatment in Example 1 (germinated black rice extract) and Comparative Example 1 (minoxidil, 'MIX').
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
화장료 조성물cosmetic composition
본 발명은 유효물질을 포함하는 화장료 조성물을 제공한다.The present invention provides a cosmetic composition containing an active substance.
상기 화장료 조성물은, 예를 들면 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산제의 형태일 수 있다. 더욱 구체적인 형태로는 화장수, 유액, 크림, 스킨, 로션, 세럼, 에센스, 에멀젼, 파우더, 화장연고, 스프레이, 젤, 팩, 클렌저, 비누, 샴푸, 린스, 입욕제, 세정제 또는 콘실 스틱의 형태로 제공될 수 있다. 또한, 폼(foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 제조될 수 있다.The cosmetic compositions include, for example, solutions, gels, solid or pasty anhydrous products, emulsions obtained by dispersing the oil phase in the water phase, suspensions, microemulsions, microcapsules, microgranules, or ionic (liposome) and non-ionic vesicular dispersants. It may be in the form of . More specifically, it is provided in the form of lotion, emulsion, cream, skin, lotion, serum, essence, emulsion, powder, cosmetic ointment, spray, gel, pack, cleanser, soap, shampoo, rinse, bath salt, cleanser, or concealer stick. It can be. Additionally, it can be manufactured in the form of foam or in the form of an aerosol composition further containing compressed propellant.
또한, 상기 화장료 조성물은 본 발명의 유효물질에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.In addition to the active substances of the present invention, the cosmetic composition contains fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, Commonly used in water, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or in cosmetics. It may contain auxiliaries commonly used in the cosmetic field, such as any other ingredients.
본 발명의 유효물질을 함유하는 화장료 조성물에 있어서, 통상적으로 함유되는 화장료 조성물에 본 발명의 유효물질이 0.1 내지 50 중량%, 바람직하게는 1 내지 10 중량%의 양으로 첨가될 수 있다.In a cosmetic composition containing the active substance of the present invention, the active substance of the present invention may be added in an amount of 0.1 to 50% by weight, preferably 1 to 10% by weight, in a cosmetic composition that is usually contained.
본 발명의 유효물질을 피부 외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한, 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.When the active substance of the present invention is used as an external skin agent, fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, and surfactants are added. , water, ionic or non-ionic emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, blocking agents, humectants, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or in external preparations for the skin. It may contain adjuvants commonly used in the field of dermatology, such as any other ingredients used. Additionally, the ingredients may be introduced in amounts commonly used in the field of dermatology.
건강식품 및 건강기능성식품 조성물Health food and health functional food composition
식품의 종류에는 특별한 제한은 없으며, 통상적인 의미에서의 건강식품 및 건강기능성식품을 모두 포함한다.There are no special restrictions on the type of food, and it includes both health foods and health functional foods in the usual sense.
건강식품의 예로는 드링크제, 육류, 소세지, 빵, 캔디류, 스넥류, 면류, 아이스크림, 유제품, 스프, 이온음료, 음료수, 알코올 음료, 껌, 차 등을 들 수 있다.Examples of health foods include drinks, meat, sausages, bread, candies, snacks, noodles, ice cream, dairy products, soups, isotonic drinks, beverages, alcoholic beverages, gum, and tea.
건강기능식품의 예로는 정제, 캡슐제, 환제, 액제 형태 등의 건강기능성식품을 들 수 있다.Examples of health functional foods include health functional foods in the form of tablets, capsules, pills, and liquids.
본 발명에 따른 유효물질을 함유하는 건강식품 및 건강기능성식품 조성물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효물질의 혼합량은 그의 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 건강식품 및 건강기능성식품 중의 상기 조성물의 양은 전체 식품 중량의 0.1 내지 90 중량부로 가할 수 있다. 그러나 건강 유지를 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.Health food and health functional food compositions containing the active substances according to the present invention can be added as is to food or used together with other foods or food ingredients, and can be used appropriately according to conventional methods. The mixing amount of the effective substance can be appropriately determined depending on the purpose of use (prevention or improvement). In general, the amount of the composition in health foods and health functional foods can be 0.1 to 90 parts by weight of the total weight of the food. However, in the case of long-term intake for the purpose of maintaining health or regulating health, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
본 발명의 건강식품 및 건강기능성식품 조성물은 지시된 비율로 필수 성분으로서 본 발명 유효물질을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트라이톨 등의 당알코올이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강기능성 식품 조성물 100 당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health food and health functional food composition of the present invention has no particular restrictions on other ingredients other than containing the active substance of the present invention as an essential ingredient in the indicated ratio, and, like a typical beverage, various flavoring agents or natural carbohydrates are added as additional ingredients. It may contain. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g, per 100 of the health functional food composition of the present invention.
상기 외에 본 발명의 유효물질을 함유하는 건강식품 및 건강기능성식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강식품 및 건강기능성식품 조성물은 천연 과일쥬스 및 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition to the above, health food and health functional food compositions containing the active substances of the present invention include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, colorants, and additives (cheese, chocolate, etc.) ), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the health food and health functional food composition of the present invention may contain pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 유효물질을 함유하는 건강식품 및 건강기능성식품 조성물 100 중량부 당 0.1 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.These ingredients can be used independently or in combination. The ratio of these additives is not that important, but is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the health food or health functional food composition containing the active substance of the present invention.
약학적 조성물pharmaceutical composition
본 발명의 유효물질은 임상 투여시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있으며, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 제조된다.The active substance of the present invention can be administered in various oral and parenteral dosage forms during clinical administration, and when formulated, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants are used. It is manufactured.
경구투여를 위한 고형 제제에는 정제, 환자, 산제, 과립제, 캡슐제, 트로키제 등이 포함되며, 이러한 고형 제제는 하나 이상의 본 발명의 유효물질에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로스(sucrose), 락토오스(lactose) 또는 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제 또는 시럽제 등이 해당되는데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid preparations for oral administration include tablets, tablets, powders, granules, capsules, troches, etc. These solid preparations include one or more active substances of the present invention and at least one or more excipients, such as starch, calcium carbonate, It is prepared by mixing sucrose, lactose, or gelatin. Additionally, in addition to simple excipients, lubricants such as magnesium styrate talc are also used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, or syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, they contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. You can.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁용제, 유제, 동결건조제제, 좌제 등이 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤, 젤라틴 등이 사용될 수 있다.Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, etc. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurel, glycerol, gelatin, etc. can be used.
또한, 본 발명의 유효물질의 인체에 대한 효과적인 투여량은 환자의 나이, 몸무게, 성별, 투여형태, 건강상태 및 질환 정도에 따라 달라질 수 있으며, 일반적으로 약 0.001-100 mg/kg/일이며, 바람직하게는 0.01-35 mg/kg/일이다. 몸무게가 70㎏인 성인 환자를 기준으로 할 때, 일반적으로 0.07-7000 mg/일이며, 바람직하게는 0.7-2500 ㎎/일이며, 의사 또는 약사의 판단에 따라 일정시간 간격으로 1일 1회 내지 수회로 분할 투여할 수도 있다.In addition, the effective dosage of the active substance of the present invention to the human body may vary depending on the patient's age, weight, gender, dosage form, health condition, and disease level, and is generally about 0.001-100 mg/kg/day. Preferably it is 0.01-35 mg/kg/day. Based on an adult patient weighing 70 kg, the dose is generally 0.07-7000 mg/day, preferably 0.7-2500 mg/day, and is administered once a day at regular intervals depending on the judgment of the doctor or pharmacist. It may be administered in several divided doses.
피부 외용제external skin preparation
본 발명의 조성물에 포함되는 성분은 상기 유효성분 이외에 피부 외용제 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체, 부형제 및/또는 희석제를 포함할 수 있다. 제제화에 적합한 담체, 부형제 및 희석제의 예로는, 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말디톨, 전분, 아카시아고무, 알지네이트, 젤라틴, 칼슘포스페이트, 칼슘실리케이트, 셀룰로즈, 메틸셀룰로즈, 미정질셀룰로즈, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘스테아레이트 또는 광물유 등이 사용될 수 있다.Ingredients included in the composition of the present invention may include ingredients commonly used in external skin compositions in addition to the above active ingredients, such as conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and May include carriers, excipients and/or diluents. Examples of carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, Methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil may be used.
의약품에 적용할 경우에는 통상 사용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 비경구 투여제로 제제화할 수 있다.When applied to pharmaceuticals, commonly used inorganic or organic carriers can be added to formulate parenteral administration in solid, semi-solid or liquid form.
본 발명의 유효성분을 제제화하기 위해서는 상법에 따라서 실시하면 용이하게 제제화할 수 있으며 계면활성제, 부형제, 착색료, 향신료, 보존제, 안정제, 완충제, 현탁제, 기타 상용화하는 보조제를 적당히 사용할 수 있다.In order to formulate the active ingredient of the present invention, it can be easily formulated by carrying out conventional methods, and surfactants, excipients, colorants, spices, preservatives, stabilizers, buffers, suspending agents, and other commercially available auxiliaries can be appropriately used.
본 발명의 피부 외용제 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 연고, 패치, 젤, 크림 또는 분무제의 형태로 제형화될 수 있으나, 이에 한정되는 것은 아니다.The composition for topical skin application of the present invention can be prepared in any formulation commonly prepared in the art, for example, in the form of ointment, patch, gel, cream or spray, but is not limited thereto. .
이하, 본 발명을 하기의 실시예에 의하여 더욱 상세하게 설명한다. 단, 하기의 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기의 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through the following examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following examples.
<실시예 1> 발아 흑미 및 발효 돼지감자 복합 추출물의 제조<Example 1> Preparation of complex extract of sprouted black rice and fermented pork potato
'발아' 흑미 100g을 70% 에탄올 1L에 첨가하여 실온에서 24시간 동안 3회 반복 추출하여 추출액을 얻었으며, 상기 추출액을 여과 농축한 후, 동결건조하여 분말화하였다.100g of 'germinated' black rice was added to 1L of 70% ethanol and extracted three times at room temperature for 24 hours to obtain an extract. The extract was filtered and concentrated, then freeze-dried and powdered.
생물자원센터 KCCM 12116 Lactibacillus plantarum 균주를 분양받아 MRS Agar 배지에 배양하여 괴산 돼지감자 건조 분쇄분말 70% EtOH 80℃ 2DAY 열수 농축물 400ml에 V/V 5% 만큼 접종하고, 48시간 동안 37℃의 인큐베이터에 배양하여 돼지 감자 유산균 생물전환 결과물을 얻었고 이를 동결 건조하여 시료로 사용하였다.Biological Resource Center KCCM 12116 Lactibacillus plantarum strain was purchased, cultured on MRS Agar medium, inoculated at 5% V/V into 400ml of dried ground pork potato powder, 70% EtOH, 80℃, 2DAY, hot water concentrate, and placed in an incubator at 37℃ for 48 hours. By culturing the pig potato lactic acid bacteria bioconversion result, it was freeze-dried and used as a sample.
상기 발아 흑미 추출물 시료 및 발효 돼지감자 시료를 1:1의 중량비로 혼합하여 발아 흑미 및 발효 돼지감자 복합 추출물을 제조하였다.The germinated black rice extract sample and the fermented pork potato sample were mixed at a weight ratio of 1:1 to prepare a complex extract of the sprouted black rice and fermented pork potato.
<비교예 1> 미녹시딜<Comparative Example 1> Minoxidil
비교예 1로서 미녹시딜(minoxidil, 이하 'MIX'로 표기함)을 준비하였다.As Comparative Example 1, minoxidil (hereinafter referred to as 'MIX') was prepared.
<비교예 2> 발아하지 않은 일반 흑미 추출물의 제조<Comparative Example 2> Preparation of non-germinated regular black rice extract
발아하지 않은 '일반' 흑미 100g을 70% 에탄올 1L에 첨가하여 실온에서 24시간 동안 3번 반복추출하였으며, 추출액을 여과 농축 한 후, 동결건조하여 분말화하였다.100g of ungerminated 'normal' black rice was added to 1L of 70% ethanol and extracted repeatedly three times for 24 hours at room temperature. The extract was filtered and concentrated, then freeze-dried and powdered.
<비교예 3> 발아 흑미(<Comparative Example 3> Germinated black rice ( Oryza sativaOryza sativa L.) 추출물의 제조 L.) Preparation of extract
'발아' 흑미 100g을 70% 에탄올 1L에 첨가하여 실온에서 24시간 동안 3회 반복 추출하여 추출액을 얻었으며, 상기 추출액을 여과 농축한 후, 동결건조하여 분말화하였다.100g of 'germinated' black rice was added to 1L of 70% ethanol and extracted three times at room temperature for 24 hours to obtain an extract. The extract was filtered and concentrated, then freeze-dried and powdered.
<실험예 1> 진피 모유두세포의 증식 및 분화 촉진 효능 평가(Scratch test)<Experimental Example 1> Evaluation of the efficacy of promoting proliferation and differentiation of dermal dermal papilla cells (Scratch test)
Control: 인간 모유두 세포(Humam dermal papilla cell, HDPCs)에 어떠한 처리도 하지 않은 군Control: A group in which no treatment was performed on human dermal papilla cells (HDPCs).
Negative control: H2O2를 처리함으로써 인간 모유두 세포에 stress를 유발한 후 어떠한 처리도 하지 않은 군 Negative control: A group in which stress was induced in human hair papilla cells by treatment with H 2 O 2 and then no treatment was performed.
Positive control: H2O2를 처리함으로써 모유두 세포에 stress를 유발한 후 상기 인간 모유두 세포에 비교예 1(미녹시딜, 'MIX')을 처리한 군Positive control: A group in which stress was induced in dermal papilla cells by treatment with H 2 O 2 and then the human dermal papilla cells were treated with Comparative Example 1 (minoxidil, 'MIX')
실험군: H2O2를 처리함으로써 모유두 세포에 stress를 유발한 후 상기 인간 모유두 세포에 실시예 1(발아 흑미 및 발효 돼지감자 복합 추출물) 및 비교예 3(발아 흑미 추출물)을 처리한 군Experimental group: A group in which stress was induced in dermal papilla cells by treatment with H 2 O 2 and then the human dermal papilla cells were treated with Example 1 (sprouted black rice and fermented pork potato complex extract) and Comparative Example 3 (sprouted black rice extract).
인간 모유두 세포를 6 well plate에 접종한 후 2일 뒤 각 well을 100μL 멸균 팁으로 긁은 후 Control을 제외한 상기 3개의 군을 H2O2를 처리 후 비교예 1(미녹시딜, 'MIX')과 실시예 1(발아 흑미 및 발효 돼지감자 복합 추출물), 비교예 3(발아 흑미 추출물)을 처리한 뒤 0hr, 24hr의 시점에서 긁힌 부분을 촬영하였다.After inoculating human dermal papilla cells in a 6-well plate, 2 days later, each well was scraped with a 100μL sterilized tip, and the above three groups, excluding Control, were treated with H 2 O 2 and then performed with Comparative Example 1 (minoxidil, 'MIX') After treatment of Example 1 (sprouted black rice and fermented pork potato complex extract) and Comparative Example 3 (sprouted black rice extract), the scratched portion was photographed at 0 hr and 24 hr.
도 1은 실시예 1(발아 흑미 및 발효 돼지감자 복합 추출물) 및 비교예 1(미녹시딜, 'MIX'), 비교예 3(발아 흑미 추출물) 처리에 따른 진피 모유두세포에 인위적으로 가한 스크래치 복원 정도를 확인한 이미지이다.Figure 1 shows the degree of restoration of scratches artificially applied to dermal dermal papilla cells according to treatment of Example 1 (complex extract of germinated black rice and fermented pork potato), Comparative Example 1 (minoxidil, 'MIX'), and Comparative Example 3 (germinated black rice extract). This is a confirmed image.
도 1에 나타난 바와 같이, 비교예 1(미녹시딜, 'MIX') 50nM 처리군 및 실시예 1(발아 흑미 및 발효 돼지감자 복합 추출물) 10ppm 처리군은 스크래치를 가한 24시간 후에 상처가 대부분 복구되는 것을 확인하여, 발아 흑미 추출물과 발아 흑미 및 발효 돼지감자 복합 추출물이 진피 모유두세포의 증식 및 분화를 촉진할 수 있음을 확인하였으며, 실시예 1(발아 흑미 및 발효 돼지감자 복합 추출물)의 결과가 비교예 3(발아 흑미 추출물)보다 세포의 응집도가 높고 증식 및 분화를 촉진하였음을 확인하였다.As shown in Figure 1, the group treated with 50 nM of Comparative Example 1 (minoxidil, 'MIX') and the group treated with 10 ppm of Example 1 (sprouted black rice and fermented pork potato complex extract) showed that most of the wounds were recovered 24 hours after scratching. It was confirmed that the sprouted black rice extract and the complex extract of germinated black rice and fermented pork potato can promote the proliferation and differentiation of dermal hair papilla cells, and the results of Example 1 (complex extract of sprouted black rice and fermented pig potato) were compared to the comparative example. It was confirmed that the degree of cell aggregation was higher than that of 3 (germinated black rice extract) and that proliferation and differentiation were promoted.
<실험예 2> 진피 모유두세포에서 Alkaline Phosphatase 발현 촉진 효능 평가<Experimental Example 2> Evaluation of the efficacy of promoting Alkaline Phosphatase expression in dermal hair papilla cells
실험군 및 대조군은 상기 실험예 1과 동일하게 구성하였다.The experimental group and control group were configured in the same manner as in Experimental Example 1 above.
구체적으로, control을 제외한 나머지 Negative control, Positive control, 실험군은 H2O2를 처리함으로써 모유두 세포에 stress를 유발한 후 Negative control은 아무것도 처리하지 않고, Positive control은 비교예 1(미녹시딜, 'MIX')를 처리하고 마지막으로 실험군은 실시예 1(발아 흑미 및 발효 돼지감자 복합 추출물)을 처리한 후 48hr 뒤에 고정용액(4% paraformaldehyde)을 5분 동안 처리하였다. Control은 아무 처리를 하지 않고 고정용액을 처리하였다.Specifically, excluding the control, the Negative control, Positive control, and experimental groups were treated with H 2 O 2 to induce stress in the dermal papilla cells, the Negative control was not treated with anything, and the Positive control was Comparative Example 1 (minoxidil, 'MIX') ) and finally, the experimental group was treated with a fixative solution (4% paraformaldehyde) for 5 minutes 48 hours after treatment with Example 1 (sprouted black rice and fermented pork potato complex extract). Control treated the fixation solution without any treatment.
이후 각각의 군에서 상기 고정용액을 제거한 후, 각각의 군에 알칼리성 인산 가수분해 효소 기질(alkaline phosphatase substrate)을 처리한 후 일정 시간 뒤 3차 증류수로 염색된 세포를 씻은 후 현미경으로 푸른색으로 염색된 세포를 확인하였다.After removing the fixing solution from each group, each group was treated with alkaline phosphatase substrate, and after a certain period of time, the stained cells were washed with distilled water and stained blue under a microscope. cells were confirmed.
도 2는 실시예 1(발아 흑미 및 발효 돼지감자 복합 추출물) 및 비교예 1(미녹시딜, 'MIX') 처리에 따른 진피 모유두세포에서 Alkaline Phosphatase 발현량을 확인한 이미지이다.Figure 2 is an image confirming the expression level of Alkaline Phosphatase in dermal dermal papilla cells according to treatment in Example 1 (complex extract of germinated black rice and fermented pork potato) and Comparative Example 1 (minoxidil, 'MIX').
도 2에 나타난 바와 같이, 정상 대조군(Control) 대비 과산화수소(H2O2) 처리군에서 Alkaline Phosphatase 발현량이 현저히 감소함을 알 수 있다. 비교예 1(미녹시딜, 'MIX') 50nM 처리군과 및 실시예 1(발아 흑미 및 발효 돼지감자 복합 추출물) 10ppm 처리군 모두 정상 대조군 수준으로 Alkaline Phosphatase 발현이 회복되었음을 확인하여, 발아 흑미 및 발효 돼지감자 복합 추출물이 진피 모유두세포의 증식 및 분화를 촉진할 수 있음을 확인하였다.As shown in Figure 2, it can be seen that the expression level of Alkaline Phosphatase is significantly reduced in the hydrogen peroxide (H 2 O 2 ) treated group compared to the normal control group (Control). Alkaline Phosphatase expression was restored to the normal control level in both the 50nM treatment group of Comparative Example 1 (minoxidil, 'MIX') and the 10ppm treatment group of Example 1 (germinated black rice and fermented pork potato complex extract). It was confirmed that the complex extract of sprouted black rice and fermented pork potato can promote the proliferation and differentiation of dermal dermal papilla cells.
화장료의 제조예Manufacturing example of cosmetics
본 발명에 따른 유효물질은 목적에 따라 여러 형태의 화장료로 제조 가능하다. 하기는 본 발명에 따른 유효물질을 활성성분으로 함유시킨 몇몇 화장료의 제조방법을 예시한 것으로 본 발명이 이에 한정되는 것은 아니다.The active substance according to the present invention can be manufactured into various types of cosmetics depending on the purpose. The following is an example of a manufacturing method of some cosmetics containing the active substance according to the present invention as an active ingredient, and the present invention is not limited thereto.
<화장료 제조예 1> 유연 화장수의 제조<Cosmetic Preparation Example 1> Preparation of flexible lotion
유효물질 10.0 중량부Active substance 10.0 parts by weight
1,3-부틸렌글리콜 1.00 중량부1,3-butylene glycol 1.00 parts by weight
디소듐이디티에이 0.05 중량부Disodium EDTA 0.05 parts by weight
알란토인 0.10 중량부Allantoin 0.10 parts by weight
디포타슘글리시리제이트 0.05 중량부Dipotassium glycyrrhizate 0.05 parts by weight
시트르산 0.01 중량부Citric acid 0.01 parts by weight
소듐시트레이트 0.02 중량부Sodium citrate 0.02 parts by weight
글리세레스-26 1.00 중량부Glycereth-26 1.00 parts by weight
알부틴 2.00 중량부Arbutin 2.00 parts by weight
하이드로제네이티드캐스터오일 1.00 중량부Hydrogenated castor oil 1.00 parts by weight
에탄올 30.0 중량부30.0 parts by weight of ethanol
보존제 미량Trace amount of preservative
착색제 미량Trace amount of colorant
착향제 미량Trace amount of flavoring agent
정제수 잔량Purified water remaining
<화장료 제조예 2> 영양 크림의 제조<Cosmetic Preparation Example 2> Preparation of nutritional cream
유효물질 10.0 중량부Active substance 10.0 parts by weight
1,3-부틸렌글리콜 7.00 중량부7.00 parts by weight of 1,3-butylene glycol
글리세린 1.00 중량부Glycerin 1.00 parts by weight
D-판테놀 0.10 중량부D-Panthenol 0.10 parts by weight
식물 추출물 3.20 중량부3.20 parts by weight of plant extract
마그네슘알루미늄실리케이트 0.30 중량부Magnesium aluminum silicate 0.30 parts by weight
PEG-40 스테아레이트 1.20 중량부PEG-40 stearate 1.20 parts by weight
스테아르산 2.00 중량부Stearic acid 2.00 parts by weight
폴리소르베이트 60 1.50 중량부Polysorbate 60 1.50 parts by weight
친유형글리세릴스테아레이트 2.00 중량부Lipophilic glyceryl stearate 2.00 parts by weight
소르비탄세스퀴올리에이트 1.50 중량부Sorbitan sesquioleate 1.50 parts by weight
세테아릴알코올 3.00 중량부Cetearyl alcohol 3.00 parts by weight
미네랄오일 4.00 중량부Mineral oil 4.00 parts by weight
스쿠알란 3.80 중량부Squalane 3.80 parts by weight
카르릴릭/카프릭트리글리세라이드 2.80 중량부Carlylic/capric triglyceride 2.80 parts by weight
식물성오일 1.80 중량부Vegetable oil 1.80 parts by weight
디메치콘 0.40 중량부Dimethicone 0.40 parts by weight
디포슘글리시리제이트 미량Dipotium glycyrrhizate trace amount
알란토인 미량Trace amounts of allantoin
소듐 히아루로네이트 미량Sodium Hyaluronate Trace
토코페릴아세테이트 적량Tocopheryl acetate appropriate amount
트리에탄올아민 적량Triethanolamine dosage
보존제 적량Preservative amount
착향제 적량Flavoring agent appropriate amount
정제수 잔량Purified water remaining
건강식품의 제조예Manufacturing example of health food
본 발명에 따른 유효물질은 목적에 따라 여러 형태의 건강식품으로 제조 가능하다. 하기는 본 발명에 따른 유효물질을 활성성분으로 함유시킨 몇몇 건강식품의 제조방법을 예시한 것으로 본 발명이 이에 한정되는 것은 아니다.The active substance according to the present invention can be manufactured into various types of health foods depending on the purpose. The following is an example of a manufacturing method of some health foods containing the active substance according to the present invention as an active ingredient, and the present invention is not limited thereto.
<건강식품 제조예 1> 유제품(dairy products)의 제조<Health food manufacturing example 1> Manufacturing of dairy products
본 발명의 유효물질 0.01-1 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.0.01-1 part by weight of the active substance of the present invention was added to milk, and various dairy products such as butter and ice cream were manufactured using the milk.
<건강식품 제조예 2> 선식의 제조<Health food production example 2> Production of sun food
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다. 검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다. 본 발명의 유효물질을 진공 농축기에서 감압농축하고 건조분말을 얻었다. 상기에서 제조한 곡물류, 종실류 및 유효물질의 건조분말을 다음의 비율로 배합하여 제조하였다.Brown rice, barley, glutinous rice, and coix seed were gelatinized and dried using a known method, roasted, and then made into powder with a particle size of 60 mesh using a grinder. Black beans, black sesame seeds, and perilla seeds were steamed and dried using a known method, roasted, and then made into powder with a particle size of 60 mesh using a grinder. The active substance of the present invention was concentrated under reduced pressure in a vacuum concentrator to obtain a dry powder. The dried powders of grains, seeds, and active substances prepared above were mixed in the following ratio.
곡물류(현미 34 중량부, 율무 19 중량부, 보리 20 중량부),Grains (34 parts by weight of brown rice, 19 parts by weight of coix radish, 20 parts by weight of barley),
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight perilla seeds, 8 parts by weight black beans, 7 parts by weight black sesame seeds),
유효물질 (2 중량부),Active substance (2 parts by weight),
영지(1.5 중량부), 및Reishi (1.5 parts by weight), and
지황(1.5 중량부).Rehmannia glutinosa (1.5 parts by weight).
건강기능식품의 제조예Manufacturing example of health functional food
본 발명에 따른 유효물질은 목적에 따라 여러 형태의 건강기능식품으로 제조 가능하다. 하기는 본 발명에 따른 유효물질을 활성성분으로 함유시킨 몇몇 건강기능식품의 제조방법을 예시한 것으로 본 발명이 이에 한정되는 것은 아니다.The active substance according to the present invention can be manufactured into various types of health functional foods depending on the purpose. The following is an example of a manufacturing method of some health functional foods containing the effective substance according to the present invention as an active ingredient, and the present invention is not limited thereto.
<건강기능식품 제조예 1> 건강기능식품의 제조<Example 1 of manufacturing health functional food> Manufacturing of health functional food
유효물질 100 mgActive substance 100 mg
비타민 혼합물 적량Vitamin mixture dosage
비타민 A 아세테이트 70 μgVitamin A acetate 70 μg
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mgVitamin B2 0.15 mg
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 μgVitamin B12 0.2 μg
비타민 C 10 mgVitamin C 10 mg
비오틴 10 μgBiotin 10 μg
니코틴산아미드 1.7 mgNicotinamide 1.7 mg
엽산 50 μg50 μg folic acid
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture appropriate amount
황산제1철 1.75 mgFerrous sulfate 1.75 mg
산화아연 0.82 mgZinc oxide 0.82 mg
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgMonobasic Potassium Phosphate 15 mg
제2인산칼슘 55 mgDibasic calcium phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mgCalcium carbonate 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강기능성 식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능성 식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능성 식품 조성물 제조에 사용할 수 있다.The composition ratio of the above vitamin and mineral mixture is a mixture of ingredients relatively suitable for health functional foods in a preferred embodiment, but the mixing ratio may be modified arbitrarily, and the above ingredients are mixed according to a typical health functional food manufacturing method. Then, granules can be prepared and used to manufacture health functional food compositions according to conventional methods.
<건강기능식품 제조예 2> 건강 기능 음료의 제조<Example 2 of manufacturing health functional food> Manufacturing of health functional beverage
유효물질 100 mgActive substance 100 mg
구연산 100 mg100 mg citric acid
올리고당 100 mg100 mg of oligosaccharides
매실농축액 2 mgPlum concentrate 2 mg
타우린 100 mgTaurine 100 mg
정제수를 가하여 전체 500 mLAdd purified water to make a total of 500 mL.
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 1 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. 상기 조성비는 비교적 기호 음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.After mixing the above ingredients according to a typical health drink manufacturing method, stirring and heating at 85°C for about 1 hour, the resulting solution was filtered, obtained in a sterilized container, sealed, sterilized, and stored in the refrigerator. Then, the present invention It is used in the production of health drink compositions. The composition ratio is a preferred embodiment of mixing ingredients relatively suitable for preferred drinks, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as demand class, demand country, and use purpose.
약제의 제조예Preparation example of medicine
본 발명에 따른 유효물질은 목적에 따라 여러 형태로 제제화가 가능하다. 하기는 본 발명에 따른 유효물질을 활성성분으로 함유시킨 몇몇 제제화 방법을 예시한 것으로 본 발명이 이에 한정되는 것은 아니다.The active substance according to the present invention can be formulated in various forms depending on the purpose. The following illustrates several formulation methods containing the effective substance according to the present invention as an active ingredient, but the present invention is not limited thereto.
<약제 제조예 1> 산제의 제조<Drug Preparation Example 1> Preparation of powder
유효물질 2 g2 g of active substance
유당 1 g1 g lactose
상기의 성분을 혼합한 후, 기밀포에 충진하여 산제를 제조하였다.After mixing the above ingredients, they were filled into an airtight bubble to prepare a powder.
<약제 제조예 2> 정제의 제조<Drug Preparation Example 2> Preparation of tablets
유효물질 100 ㎎Active substance 100 mg
옥수수전분 100 ㎎Corn starch 100 mg
유 당 100 ㎎Lactose 100 mg
스테아린산 마그네슘 2 ㎎Magnesium stearate 2 mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above ingredients, tablets were manufactured by tableting according to a conventional tablet manufacturing method.
<약제 제조예 3> 캡슐제의 제조<Drug Preparation Example 3> Preparation of capsules
유효물질 100 ㎎Active substance 100 mg
옥수수전분 100 ㎎Corn starch 100 mg
유 당 100 ㎎Lactose 100 mg
스테아린산 마그네슘 2 ㎎Magnesium stearate 2 mg
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above ingredients, a capsule was prepared by filling a gelatin capsule according to a typical capsule manufacturing method.
<약제 제조예 4> 주사제의 제조<Pharmaceutical Preparation Example 4> Preparation of injections
유효물질 10 ㎍/㎖Active substance 10 ㎍/㎖
묽은 염산 BP pH 3.5로 될 때까지Dilute hydrochloric acid BP until pH 3.5
주사용 염화나트륨 BP 최대 1 ㎖Sodium Chloride BP for Injection up to 1 ml
적당한 용적의 주사용 염화나트륨 BP 중에 본 발명에 따른 유효물질을 용해시키고, 생성된 용액의 pH를 묽은 염산 BP를 사용하여 pH 3.5로 조절하고, 주사용 염화나트륨 BP를 사용하여 용적을 조절하고 충분히 혼합하였다. 용액을 투명 유리로 된 5 ㎖ 타입 I 앰플 중에 충전시키고, 유리를 용해시킴으로써 공기의 상부 격자하에 봉입시키고, 120 ℃에서 15 분 이상 오토클래이브시켜 살균하여 주사액제를 제조하였다.The active substance according to the present invention was dissolved in an appropriate volume of sodium chloride BP for injection, the pH of the resulting solution was adjusted to pH 3.5 using diluted hydrochloric acid BP, and the volume was adjusted using sodium chloride BP for injection and thoroughly mixed. . The solution was filled into a 5 ml Type I ampoule made of transparent glass, sealed under an upper grid of air by dissolving the glass, and sterilized by autoclaving at 120°C for 15 minutes or more to prepare an injection solution.
<약제 제조예 5> 경비흡수제 (Nasal spray)의 제조<Drug Preparation Example 5> Preparation of nasal absorbent (Nasal spray)
유효물질 1.0 gActive substance 1.0 g
아세트산나트륨 0.3 gSodium acetate 0.3 g
메틸파라벤 0.1 gMethylparaben 0.1 g
프로필파라벤 0.02 gPropylparaben 0.02 g
염화나트륨 적량Sodium chloride dosage
HCl 또는 NaOH pH 조정 적량HCl or NaOH pH adjustment appropriate amount
정제수 적량Proper amount of purified water
통상의 경비흡수제의 제조방법에 따라, 염수 (0.9% NaCl, w/v, 용매는 정제수) 1 mL당 유효물질 3 mg이 포함되도록 제조하고, 이를 불투명한 스프레이 용기에 충진하고 멸균시켜 경비흡수제를 제조하였다.According to the usual manufacturing method of a nasal absorbent, it is prepared to contain 3 mg of the active substance per 1 mL of saline water (0.9% NaCl, w/v, the solvent is purified water), filled into an opaque spray container, and sterilized to prepare a nasal absorbent. Manufactured.
<약제 제조예 6> 액제의 제조<Drug Preparation Example 6> Preparation of liquid preparation
유효물질 100 mgActive substance 100 mg
이성화당 10 g10 g isomerized sugar
만니톨 5 g5 g mannitol
정제수 적량Proper amount of purified water
통상의 액제의 제조방법에 따라, 정제수에 각각의 성분을 가하여 용해시키고 레몬 향을 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체 100 mL로 조절한 후 갈색 병에 충진하고 멸균시켜 액제를 제조하였다.According to the usual liquid preparation method, add and dissolve each ingredient in purified water, add lemon zest, mix the above ingredients, add purified water to adjust the total to 100 mL, fill in a brown bottle, and sterilize to prepare the liquid. did.
피부 외용제의 제조예Manufacturing example of external skin preparation
본 발명에 따른 유효물질은 목적에 따라 여러 형태로 제제화가 가능하다. 하기는 본 발명에 따른 유효물질을 활성성분으로 함유시킨 몇몇 제제화 방법을 예시한 것으로 본 발명이 이에 한정되는 것은 아니다.The active substance according to the present invention can be formulated in various forms depending on the purpose. The following illustrates several formulation methods containing the effective substance according to the present invention as an active ingredient, but the present invention is not limited thereto.
<피부 외용제 제조예 1> 분무제의 제조<Example 1 of preparation of external skin preparation> Preparation of spray
유효물질 100 mgActive substance 100 mg
이성화당 10 g10 g isomerized sugar
만니톨 5 g5 g mannitol
정제수 적량Proper amount of purified water
통상의 분무제의 제조방법에 따라, 정제수에 각각의 성분을 가하여 용해시키고 레몬 향을 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체 100 mL로 조절한 후 갈색 병에 충진하고 멸균시켜 분무제를 제조하였다.According to a typical spray manufacturing method, add and dissolve each ingredient in purified water, add lemon scent, mix the above ingredients, add purified water to adjust the total to 100 mL, fill in a brown bottle, and sterilize to prepare the spray. did.
<피부 외용제 제조예 2> 젤제의 제조<Example 2 of preparation of external skin preparation> Preparation of gel
유효물질 100 mgActive substance 100 mg
에탄올 10 g10 g of ethanol
글리세린 4 g4 g glycerin
프로필렌글리콜 4 g4 g propylene glycol
폴리옥시에틸렌 경화피마자유 0.1 g0.1 g polyoxyethylene hydrogenated castor oil
카르복시폴리머 0.3 gCarboxypolymer 0.3 g
트리에탄올아민 0.3gTriethanolamine 0.3g
산화방지제 적량Antioxidant dosage
향료 적량Spice Proper Amount
방부제 적량Preservative dosage
정제수 적량Proper amount of purified water
통상의 젤제의 제조방법에 따라, 정제수에 각각의 성분을 가하여 용해시키고 향료를 가한 다음 상기의 성분들을 혼합하여 젤제를 제조하였다.According to a typical gel preparation method, each ingredient was added and dissolved in purified water, fragrance was added, and the above ingredients were mixed to prepare a gel.
<피부 외용제 제조예 3> 연고제의 제조<Example 3 of preparation of external skin preparation> Preparation of ointment
유효물질 100 mgActive substance 100 mg
세토스테아릴알코올 2 g2 g cetostearyl alcohol
자가유화형 모노스테아린산 2 gSelf-emulsifying monostearic acid 2 g
스테아린산 1 g1 g stearic acid
밀납 4 g4 g beeswax
스쿠알란 7 g7 g of squalane
모노스테아린 글리세린 3 gMonostearin glycerin 3 g
모노스테아린산 소르비탄 1 g1 g sorbitan monostearate
폴리솔베이트 80 3 gPolysorbate 80 3 g
글리세린 5 g5 g glycerin
프로필렌글리콜 4 g4 g propylene glycol
향료 적량Spice Proper Amount
바세린 잔량Vaseline remaining amount
통상의 연고제의 제조방법에 따라, 바세린에 각각의 성분을 가하여 용해시키고 향료를 가한 다음 상기의 성분들을 혼합하여 연고제를 제조하였다.According to a typical ointment manufacturing method, each ingredient was added and dissolved in vaseline, fragrance was added, and the above ingredients were mixed to prepare an ointment.
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특히 청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far, the present invention has been examined focusing on its preferred embodiments. A person skilled in the art to which the present invention pertains will understand that the present invention may be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative rather than a restrictive perspective. The scope of the present invention is set forth in particular in the claims rather than the foregoing description, and all differences within the equivalent scope should be construed as being included in the present invention.
Claims (8)
상기 발효 돼지감자는 락토바실러스 플란타룸(Lactibacillus plantarum) KCCM 12116 균주로 발효되며,
상기 발아 흑미 및 발효 돼지감자는 1:1 중량비로 혼합되고,
상기 발아 흑미 및 발효 돼지감자 복합 추출물은 모유두세포의 증식 또는 분화를 촉진시키며, 알칼라인 포스파테이즈(Alkaline phosphatase)의 발현을 증가시키는 것인, 조성물.
A cosmetic composition for preventing or improving hair loss containing a complex extract of sprouted black rice and fermented pork potato as an active ingredient,
The fermented pork potato is fermented with Lactobacillus plantarum KCCM 12116 strain,
The germinated black rice and fermented pork potatoes are mixed in a 1:1 weight ratio,
A composition wherein the complex extract of sprouted black rice and fermented pork potato promotes the proliferation or differentiation of dermal papilla cells and increases the expression of alkaline phosphatase.
상기 화장료는 화장수, 유액, 크림, 스킨, 로션, 세럼, 에센스, 에멀젼, 파우더, 화장연고, 스프레이, 젤, 팩, 클렌저, 비누, 샴푸, 린스, 입욕제, 세정제 또는 콘실 스틱의 형태인 것을 특징으로 하는 화장료 조성물.
According to clause 1,
The cosmetics are in the form of lotion, emulsion, cream, skin, lotion, serum, essence, emulsion, powder, cosmetic ointment, spray, gel, pack, cleanser, soap, shampoo, rinse, bath salt, detergent, or concealer stick. Cosmetic composition.
상기 발효 돼지감자는 락토바실러스 플란타룸(Lactibacillus plantarum) KCCM 12116 균주로 발효되며,
상기 발아 흑미 및 발효 돼지감자는 1:1 중량비로 혼합되고,
상기 발아 흑미 및 발효 돼지감자 복합 추출물은 모유두세포의 증식 또는 분화를 촉진시키며, 알칼라인 포스파테이즈(Alkaline phosphatase)의 발현을 증가시키는 것인, 조성물.
A food composition for preventing or improving hair loss containing a complex extract of sprouted black rice and fermented pork potato as an active ingredient,
The fermented pork potato is fermented with Lactobacillus plantarum KCCM 12116 strain,
The germinated black rice and fermented pork potatoes are mixed in a 1:1 weight ratio,
A composition wherein the complex extract of sprouted black rice and fermented pork potato promotes the proliferation or differentiation of dermal papilla cells and increases the expression of alkaline phosphatase.
상기 식품은 드링크제, 육류, 소세지, 빵, 캔디류, 스넥류, 면류, 아이스크림, 유제품, 스프, 이온음료, 음료수, 알코올 음료, 껌 또는 차의 형태인 것을 특징으로 하는 식품 조성물.
According to clause 3,
A food composition characterized in that the food is in the form of drinks, meat, sausages, bread, candies, snacks, noodles, ice cream, dairy products, soups, isotonic drinks, beverages, alcoholic beverages, gum or tea.
상기 발효 돼지감자는 락토바실러스 플란타룸(Lactibacillus plantarum) KCCM 12116 균주로 발효되며,
상기 발아 흑미 및 발효 돼지감자는 1:1 중량비로 혼합되고,
상기 발아 흑미 및 발효 돼지감자 복합 추출물은 모유두세포의 증식 또는 분화를 촉진시키며, 알칼라인 포스파테이즈(Alkaline phosphatase)의 발현을 증가시키는 것인, 조성물.
A health functional food composition for preventing or improving hair loss containing a complex extract of sprouted black rice and fermented pork potato as an active ingredient,
The fermented pork potato is fermented with Lactobacillus plantarum KCCM 12116 strain,
The germinated black rice and fermented pork potatoes are mixed in a 1:1 weight ratio,
A composition wherein the complex extract of sprouted black rice and fermented pork potato promotes the proliferation or differentiation of dermal papilla cells and increases the expression of alkaline phosphatase.
상기 건강기능식품은 정제, 캡슐제, 환제 또는 액제 형태인 것을 특징으로 하는 건강기능식품 조성물.
According to clause 5,
The health functional food composition is characterized in that the health functional food is in the form of tablets, capsules, pills or liquid.
상기 발효 돼지감자는 락토바실러스 플란타룸(Lactibacillus plantarum) KCCM 12116 균주로 발효되며,
상기 발아 흑미 및 발효 돼지감자는 1:1 중량비로 혼합되고,
상기 발아 흑미 및 발효 돼지감자 복합 추출물은 모유두세포의 증식 또는 분화를 촉진시키며, 알칼라인 포스파테이즈(Alkaline phosphatase)의 발현을 증가시키는 것인, 조성물.
A pharmaceutical composition for preventing or treating hair loss containing a complex extract of sprouted black rice and fermented pork potato as an active ingredient,
The fermented pork potato is fermented with Lactobacillus plantarum KCCM 12116 strain,
The germinated black rice and fermented pork potatoes are mixed in a 1:1 weight ratio,
A composition wherein the complex extract of sprouted black rice and fermented pork potato promotes the proliferation or differentiation of dermal papilla cells and increases the expression of alkaline phosphatase.
상기 약학적 조성물은 피부 외용제 형태인 것을 특징으로 하는 약학적 조성물.According to clause 7,
A pharmaceutical composition, characterized in that the pharmaceutical composition is in the form of an external preparation for skin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020230109336A KR102632060B1 (en) | 2023-08-21 | 2023-08-21 | Composition for preventing alopesia comprising germinated black rice extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020230109336A KR102632060B1 (en) | 2023-08-21 | 2023-08-21 | Composition for preventing alopesia comprising germinated black rice extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102632060B1 true KR102632060B1 (en) | 2024-02-01 |
Family
ID=89859179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020230109336A KR102632060B1 (en) | 2023-08-21 | 2023-08-21 | Composition for preventing alopesia comprising germinated black rice extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102632060B1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007246446A (en) * | 2006-03-16 | 2007-09-27 | Sansho Seiyaku Co Ltd | External preparation for skin or hair |
KR100778662B1 (en) | 2006-06-14 | 2007-11-29 | 나드리화장품주식회사 | Cleansing composition containing natural oriental plant extracts |
KR20150081892A (en) * | 2014-01-07 | 2015-07-15 | 주식회사 코리아나화장품 | Cosmetic composition comprising the extract of Helianthus Tuberosus Root |
KR102493443B1 (en) * | 2022-08-29 | 2023-01-31 | 주식회사 잇츠한불 | Cosmetic composition comprising extracts extracted with an eco-friendly natural eutectic solvent |
-
2023
- 2023-08-21 KR KR1020230109336A patent/KR102632060B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007246446A (en) * | 2006-03-16 | 2007-09-27 | Sansho Seiyaku Co Ltd | External preparation for skin or hair |
KR100778662B1 (en) | 2006-06-14 | 2007-11-29 | 나드리화장품주식회사 | Cleansing composition containing natural oriental plant extracts |
KR20150081892A (en) * | 2014-01-07 | 2015-07-15 | 주식회사 코리아나화장품 | Cosmetic composition comprising the extract of Helianthus Tuberosus Root |
KR102493443B1 (en) * | 2022-08-29 | 2023-01-31 | 주식회사 잇츠한불 | Cosmetic composition comprising extracts extracted with an eco-friendly natural eutectic solvent |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101909236B1 (en) | Composition for improving skin wrinkle and enhancing elasticity | |
US20090269424A1 (en) | Peripheral blood flow-improving composition | |
US10967028B2 (en) | Composition for hair loss prevention or hair growth stimulation comprising Artemisia umbelliformis extract | |
KR101292837B1 (en) | Composition for skin wrinkle improvement comprising extracts of Junglans mandshurica MAXIM as an active ingredient | |
KR101295368B1 (en) | Composition for skin wrinkle improvement comprising extracts of honeybush extract or its fermentation solution as an active ingredient | |
KR101419464B1 (en) | The composition comprising the extract or fraction of Pleurotus eryngii var. ferulae for prevention of anti aging as an active ingredient | |
US10568830B2 (en) | Composition for hair loss prevention or hair growth stimulation comprising Scutellaria alpina extract | |
KR102632060B1 (en) | Composition for preventing alopesia comprising germinated black rice extracts | |
KR102176883B1 (en) | Composition for skin regeneration, anti-wrinkle, or wound healing containing Prunus persica resin | |
KR101579500B1 (en) | Skin whitening composition comprising an extract obtained from roots of coix lachryma-jobi var. mayuen | |
KR20100133090A (en) | Composition comprising extracts of cudraniae fructus for treating and preventing apotic dermatitis as an active ingredient | |
KR20230126811A (en) | Composition for preventing alopesia comprising germinated black rice extracts | |
KR102579105B1 (en) | Compositions for skin whitening, UV protection, and anti skin cancer through enzymatic conversion of Luffa aegyptiaca extracts using probioticst | |
KR102517664B1 (en) | Composition for preventing, improving or treating hair loss and method for preparing the same | |
KR102355138B1 (en) | Composition for whitening or anti-wrinkle of the skin comprising fermentated ziziphus jujuba seed as effective component | |
KR102109590B1 (en) | Composition for improving wrinkle and enhancing skin elasticity containing Ginsenoside C-Mx1 | |
KR20230058205A (en) | Pharmaceutical composition for preventing or treating hair loss comprising coix seed extract and minoxidil | |
KR101609436B1 (en) | Composition including the compound derived from Hypnea japonica for prevention of hair loss or for promoting hair growth | |
KR20200124347A (en) | Composition for preventing hair loss or promoting hair growth comprising a plant extract from which chlorophyll or pigment is removed and the manufacturing methods | |
KR20180104960A (en) | Composition comprising extracts of banana, cherry, and walnut for anti-skin aging | |
KR20140132566A (en) | Composition for preventing hair loss and growing hair using fraction of unripe astringent persimmon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |